Study of INKmune in Patients With mCRPC (CaRe Prostate)
Cancer · Metastatic Castration-resistant Prostate Cancer · mCRPC
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Sep 2025, none posted yet
Counts until it's fixed
Score over time
- Stage
- Phase 1/2
- Patients
- 12 (final count)
- Started
- Nov 30, 2023
- Main results expected
- Sep 10, 2025
- Fully finished
- Sep 10, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Determine the optimal concentration of INKmune therapy to be used in patients with mCRPC.
Measured over: 2-3 years
Determine the optimal concentration of INKmune therapy to be used in patients with mCRPC.
Measured over: 2-3 years
Determine the optimal concentration of INKmune therapy to be used in patients with mCRPC.
Measured over: 2-3 years
Determine the optimal concentration of INKmune therapy to be used in patients with mCRPC.
Measured over: 2-3 years
Evaluate the safety and tolerability of INKmune therapy in patients with mCRPC.
Measured over: 2-3 years
Evaluate the safety and tolerability of INKmune therapy in patients with mCRPC.
Measured over: 2-3 years
Evaluate the safety and tolerability of INKmune therapy in patients with mCRPC.
Measured over: 2-3 years
Evaluate the safety and tolerability of INKmune therapy in patients with mCRPC.
Measured over: 2-3 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-09-10, no fading
Raw record changes
- none yet
Trial ID NCT06056791 · record last updated 2026-02-27 · checked 2026-11-09 15:47 UTC